Qiangyuan Tian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Qiangyuan Tian has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Binbin Ren
Department of Cerebrovascular Diseases Center, Linyi Traditional Chinese Medical Hospital, Linyi City, China
1 shared publicationFei Bd Gao
College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China
1 shared publication- Fei Bd Teng
College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China
1 shared publication - Guangchao Zhu
State Key Laboratory of Eco-hydraulics in Northwest Arid Region, Xi’an University of Technology, Xi’an, China
1 shared publication - Haowei Bd Guan
College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China
1 shared publication Hua Yin
Department of Cerebrovascular Diseases Center, Linyi Traditional Chinese Medical Hospital, Linyi City, China
1 shared publication
Latest Publications
- Open Access
- 3 November 2023
- Published by Wolters Kluwer Health in Medicine
- Vol. 102 (44) , e35793
Exploring the pathogenesis of depression and potential antidepressants through the integration of reverse network pharmacology, molecular docking, and molecular dynamics
Depression is characterized by a significant and persistent decline in mood and is currently a major threat to physical and mental health. Traditional Chinese medicine can effectively treat depression with few adverse effects. Therefore, this study aimed to examine the use of reverse network pharmacology and computer simulations to identify effective ingredients and herbs for treating depression. Differentially expressed genes associated with depression were obtained from the Gene Expression Omnibus database, after which enrichment analyses were performed. A protein-protein interaction network was constructed using the STRING database to screen core targets. The Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform database was used to screen ingredients related to these core targets, and the core ingredients were screened by constructing the “Targets-Ingredients-Herbs” network. Drug evaluation analysis was performed using the SwissADME and ADMETlab platforms, according to Lipinski Rule of 5. The binding between the targets and ingredients was simulated using molecular docking software. The binding stability was determined using molecular dynamics analysis. The “Ingredients-Herbs” network was constructed, and we annotated it for its characteristics and meridians. Finally, the selected herbs were classified to determine the formulation for treating depression in traditional Chinese medicine. The pathogenesis of depression was associated with changes in SPP1, Plasminogen activator inhibitor 1, CCNB1 protein, CCL3, and other genes. Computer simulations have verified the use of quercetin, luteolin, apigenin, and other ingredients as drugs for treating depression. Most of the top 10 herbs containing these ingredients were attributed to the liver meridian, and their taste was symplectic. Perilla Frutescen, Cyperi Rhizoma, and Linderae Radix, the main components of “Tianxiang Zhengqi Powder,” can treat depression owing to Qi stagnation. Epimedium and Citicola, the main traditional Chinese herbs in “Wenshen Yiqi Decoction,” have a positive effect on depression of the Yang asthenia type. Fructus Ligustri Lucidi and Ecliptae Herba are from the classic prescription “Erzhi Pills” and can treat depression of the Yin deficiency type. This study identified the key targets and effective medicinal herbs for treating depression. It provides herbal blend references for treating different types of depression according to the theory of traditional Chinese medicine.
- 3 November 2023
- Published by Wolters Kluwer Health in Medicine
- Vol. 102 (44) , e35793
Open AccessExploring the pathogenesis of depression and potential antidepressants through the integration of reverse network pharmacology, molecular docking, and molecular dynamics
Depression is characterized by a significant and persistent decline in mood and is currently a major threat to physical and mental health. Traditional Chinese medicine can effectively treat depression with few adverse effects. Therefore, this study aimed to examine the use of reverse network pharmacology and computer simulations to identify effective ingredients and herbs for treating depression. Differentially expressed genes associated with depression were obtained from the Gene Expression Omnibus database, after which enrichment analyses were performed. A protein-protein interaction network was constructed using the STRING database to screen core targets. The Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform database was used to screen ingredients related to these core targets, and the core ingredients were screened by constructing the “Targets-Ingredients-Herbs” network. Drug evaluation analysis was performed using the SwissADME and ADMETlab platforms, according to Lipinski Rule of 5. The binding between the targets and ingredients was simulated using molecular docking software. The binding stability was determined using molecular dynamics analysis. The “Ingredients-Herbs” network was constructed, and we annotated it for its characteristics and meridians. Finally, the selected herbs were classified to determine the formulation for treating depression in traditional Chinese medicine. The pathogenesis of depression was associated with changes in SPP1, Plasminogen activator inhibitor 1, CCNB1 protein, CCL3, and other genes. Computer simulations have verified the use of quercetin, luteolin, apigenin, and other ingredients as drugs for treating depression. Most of the top 10 herbs containing these ingredients were attributed to the liver meridian, and their taste was symplectic. Perilla Frutescen, Cyperi Rhizoma, and Linderae Radix, the main components of “Tianxiang Zhengqi Powder,” can treat depression owing to Qi stagnation. Epimedium and Citicola, the main traditional Chinese herbs in “Wenshen Yiqi Decoction,” have a positive effect on depression of the Yang asthenia type. Fructus Ligustri Lucidi and Ecliptae Herba are from the classic prescription “Erzhi Pills” and can treat depression of the Yin deficiency type. This study identified the key targets and effective medicinal herbs for treating depression. It provides herbal blend references for treating different types of depression according to the theory of traditional Chinese medicine.
- 11 July 2022
- Published by Springer Nature in Applied Biochemistry and Biotechnology
- Vol. 194 (12) , 5767-5780
Neuroprotective, Anti-inflammatory Effect of Furanochrome, Visnagin Against Middle Cerebral Ischemia-Induced Rat Model
In recent years, the medical field had significantly progressed to a greater extent which was evidenced with increased life expectancy and decreased mortality rate. Due to the growth of medical field, numerous communicable diseases are prevented and eradicated, whereas the non-communicable disease incidence has been increased globally. One such non-communicable disease which threatens the global population is stroke. Stroke tends to be the second leading cause of death and disability in older population. In lower- and middle-income countries, increased incidence rate of stroke was also evidenced in younger population which is alarming. Lifestyle changes, poor physical activity, stress, consumption of alcohol, oral contraception, and smoking tend to be the causative agents of stroke. Since thrombus formation is the major pathology of stroke, drugs were targeted to thrombolysis. Currently thrombolytic, antiplatelet, and anticoagulant therapies were given for the stroke patients. But the recovery rate of stroke patients with available drugs is very slow. Hence, it is a need of today to discover a drug with increased recovery rate and decreased or nil side effects. Phytochemicals are the best options to treat such non-communicable chronic diseases. Visnagin is one such compound which is used to regulate blood pressure, treat kidney stones, tumors of bile duct, renal colic, and whooping cough. It possesses anti-inflammatory, neuroprotective, and cardioprotective properties; it was also proven to treat epileptic seizures. In this study, the anti-ischemic effect of a furanochrome visnagin was assessed in in vivo rat model. Middle cerebral ischemic/reperfusion was induced in healthy male Sprague Dawley rats and treated with different concentrations of visnagin. The neuroprotective effect of visnagin against cerebral ischemia-induced rats was assessed by analyzing the neurological score, brain edema, infract volume, and Evans blue leakage. The anti-inflammatory property of visnagin was assessed by quantifying proinflammatory cytokines in serum and brain tissues of cerebral ischemia-induced rats. Prostaglandin E-2, COX-2, and NFκ-β were estimated to assess the anti-ischemic effect of visnagin. Histopathological analysis with H&E staining was performed to confirm the neuroprotective effect of visnagin against cerebral ischemia. Our results authentically confirm that visnagin has prevented the inflammation in brain region of cerebral ischemia-induced rats. The neurological scoring and the quantification of PGE-2, COX-2, and NFκ-β prove the anti-ischemic effect of visnagin. Furthermore, the histopathological analysis of hippocampal region provides evidence to the neuroprotective effect of visnagin against cerebral ischemia. Overall, our study confirms visnagin as a potent alternative drug to treat stroke.
- 11 July 2022
- Published by Springer Nature in Applied Biochemistry and Biotechnology
- Vol. 194 (12) , 5767-5780
Neuroprotective, Anti-inflammatory Effect of Furanochrome, Visnagin Against Middle Cerebral Ischemia-Induced Rat Model
In recent years, the medical field had significantly progressed to a greater extent which was evidenced with increased life expectancy and decreased mortality rate. Due to the growth of medical field, numerous communicable diseases are prevented and eradicated, whereas the non-communicable disease incidence has been increased globally. One such non-communicable disease which threatens the global population is stroke. Stroke tends to be the second leading cause of death and disability in older population. In lower- and middle-income countries, increased incidence rate of stroke was also evidenced in younger population which is alarming. Lifestyle changes, poor physical activity, stress, consumption of alcohol, oral contraception, and smoking tend to be the causative agents of stroke. Since thrombus formation is the major pathology of stroke, drugs were targeted to thrombolysis. Currently thrombolytic, antiplatelet, and anticoagulant therapies were given for the stroke patients. But the recovery rate of stroke patients with available drugs is very slow. Hence, it is a need of today to discover a drug with increased recovery rate and decreased or nil side effects. Phytochemicals are the best options to treat such non-communicable chronic diseases. Visnagin is one such compound which is used to regulate blood pressure, treat kidney stones, tumors of bile duct, renal colic, and whooping cough. It possesses anti-inflammatory, neuroprotective, and cardioprotective properties; it was also proven to treat epileptic seizures. In this study, the anti-ischemic effect of a furanochrome visnagin was assessed in in vivo rat model. Middle cerebral ischemic/reperfusion was induced in healthy male Sprague Dawley rats and treated with different concentrations of visnagin. The neuroprotective effect of visnagin against cerebral ischemia-induced rats was assessed by analyzing the neurological score, brain edema, infract volume, and Evans blue leakage. The anti-inflammatory property of visnagin was assessed by quantifying proinflammatory cytokines in serum and brain tissues of cerebral ischemia-induced rats. Prostaglandin E-2, COX-2, and NFκ-β were estimated to assess the anti-ischemic effect of visnagin. Histopathological analysis with H&E staining was performed to confirm the neuroprotective effect of visnagin against cerebral ischemia. Our results authentically confirm that visnagin has prevented the inflammation in brain region of cerebral ischemia-induced rats. The neurological scoring and the quantification of PGE-2, COX-2, and NFκ-β prove the anti-ischemic effect of visnagin. Furthermore, the histopathological analysis of hippocampal region provides evidence to the neuroprotective effect of visnagin against cerebral ischemia. Overall, our study confirms visnagin as a potent alternative drug to treat stroke.
- Open Access
- 20 September 2019
- Published by Bio-Byword Scientific Publishing, Pty. Ltd. in Journal of Clinical and Nursing Research
- Vol. 3 (6)
Clinical Efficacy of Neurointerventional Catheter Thrombolysis for Cerebral Infarction
Objective: To analyze the clinical efficacy of neurointerventional catheter thrombolysis for cerebral infarction. METHODS: A total of 56 patients with cerebral infarction admitted to our hospital from April 2018 to June 2019 were enrolled for the experimental study. Two different treatments were applied to patients, and patients were divided into observation groups and controls according to different treatment methods. After grouped into two groups the control group was treated with intravenous thrombolysis. The observation group was treated with neurointerventional arterial catheter thrombolysis. The treatment effect, NIHSS score and BI index, neurological deficit score before and after treatment, and coagulation index were compared between the two groups. RESULTS: The therapeutic effect of the observation group (92.86%) was significantly different from that of the control group (67.86%), and the observation group was higher than the control group. The data of the observation group in the NIHSS score and the BI index were 5.42±1.77 and 95.64±2.15, respectively, which were better than the control group. The neurological deficit scores of the observation group before and after treatment were 19.88±6.24 and 9.14±5.81, respectively. After treatment, the difference was significant compared with the control group, p<0.05. The coagulation indexes of the observation group in FIB, PT, TT, etc. were respectively 3.68±1.04, 11.46±1.62, 15.37±2.46, all were better than the control group (2.13±0.47, 13.72±2.72, 19.85±2.62), P<0.05. Conclusion: the clinical efficacy of neurointerventional arterial catheter thrombolysis for cerebral infarction is significant, it can effectively promote the recovery of various functional conditions of patients with cerebral infarction, which is worthy of further application and promotion.
- 20 September 2019
- Published by Bio-Byword Scientific Publishing, Pty. Ltd. in Journal of Clinical and Nursing Research
- Vol. 3 (6)
Open AccessClinical Efficacy of Neurointerventional Catheter Thrombolysis for Cerebral Infarction
Objective: To analyze the clinical efficacy of neurointerventional catheter thrombolysis for cerebral infarction. METHODS: A total of 56 patients with cerebral infarction admitted to our hospital from April 2018 to June 2019 were enrolled for the experimental study. Two different treatments were applied to patients, and patients were divided into observation groups and controls according to different treatment methods. After grouped into two groups the control group was treated with intravenous thrombolysis. The observation group was treated with neurointerventional arterial catheter thrombolysis. The treatment effect, NIHSS score and BI index, neurological deficit score before and after treatment, and coagulation index were compared between the two groups. RESULTS: The therapeutic effect of the observation group (92.86%) was significantly different from that of the control group (67.86%), and the observation group was higher than the control group. The data of the observation group in the NIHSS score and the BI index were 5.42±1.77 and 95.64±2.15, respectively, which were better than the control group. The neurological deficit scores of the observation group before and after treatment were 19.88±6.24 and 9.14±5.81, respectively. After treatment, the difference was significant compared with the control group, p<0.05. The coagulation indexes of the observation group in FIB, PT, TT, etc. were respectively 3.68±1.04, 11.46±1.62, 15.37±2.46, all were better than the control group (2.13±0.47, 13.72±2.72, 19.85±2.62), P<0.05. Conclusion: the clinical efficacy of neurointerventional arterial catheter thrombolysis for cerebral infarction is significant, it can effectively promote the recovery of various functional conditions of patients with cerebral infarction, which is worthy of further application and promotion.